Angiex, Inc is a new biotechnology startup devoted to creating a vascular therapy for cancer.
Location: United States, Massachusetts, Cambridge
Investors 3
Mentions in press and media 3
| Date | Title | Description |
| 17.04.2026 | Angiex Reports AACR In Vivo Data Supporting AGX101 in Combination With Immune Checkpoint Inhibitors for Solid Tumors | Angiex Inc. is a privately held biopharmaceutical drug developer whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Angiex Inc. poster at AACR 2026 San Diego Prec... |
| 03.11.2016 | MassChallenge Boston Awards $1.5M in Zero-Equity Prizes to Top Startups | The seventh-annual MassChallenge Boston Awards brought together more than 1,500 leaders and supporters from the Boston entrepreneurial community to celebrate the MassChallenge entrepreneurs at the Boston Convention and Exhibition Center. Th... |
| - | Angiex | “Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality” |